New hope for breast cancer patients as life-extending drug now on NHS in England
In England, NHS patients with a specific type of incurable breast cancer can now access the life-extending drug Enhertu, two years after the health body NICE deemed it too expensive. The decision is welcomed by charities, but some note that many patients missed out while the drug was already available in Scotland and 26 other European countries.
Written by Roundtablefrom 2 outlets' reporting
01What happened
From Thursday, doctors in England can prescribe Enhertu for HER2-low metastatic breast cancer. NICE had previously said the drug was not good value for money. The drug is already available in Scotland and 26 other European countries. It can give patients almost seven extra months to live on average, with some living up to three years longer. This affects about 1,000 women a year in England. Wales is expected to follow shortly, but the guidance does not automatically apply to Northern Ireland.
The facts every outlet at this table agrees on.
02Every voice
One entry per outlet, in the order they should be read. Each links back to the reporting it was drawn from — check any of it.
BBC News
Read the original· bbc.co.ukHow they framed it
The BBC frames the event as a long-awaited win for campaigners, but stresses the emotional and human cost of the two-year delay, centering a patient who was previously unable to access the drug.
In their words
Charities and patients have campaigned for it to be more widely available since 2024, when NICE said Enhertu was not good value for money. Charity Breast Cancer Now said that while campaigners' 'persistence paid off', thousands of people have missed out on access to Enhertu and many have died.
The Guardian
Read the original· theguardian.comHow they framed it
The Guardian frames the event as a straightforward expansion of NHS treatment that is expected to improve survival and quality of life.
In their words
Women in England with incurable breast cancer will gain access to the life-extending drug Enhertu on the NHS. The treatment is expected to improve survival and quality of life for patients whose disease cannot be cured.
03Where they differ
The BBC includes patient testimony and critical comments from a charity about the delay and missed opportunities, while The Guardian provides a shorter report focused on the fact that the drug will now be available and its expected benefits.
Described, not adjudicated. Roundtable does not tell you which account is right.
04Still open
- How many patients died during the two-year delay before Enhertu was made available in England?
- What specific factors led to the change in the NICE recommendation?
- When exactly will Wales and Northern Ireland follow England in offering Enhertu on the NHS?
- Will the drug be equally accessible to all eligible patients across England, or might there be regional differences in implementation?
